John Ioannidis, director of the Stanford Preventative Research Center and the senior author of the study, calls for data to be made available publicly for scrutiny and analysis from different parties. Trust of clinical trials has been questioned over the years - and data analysis from multiple parties could solve that.
The Wall Street Journal is not the only news source pointing towards a more open clinical data sharing future. The Pharma Letter lists many of the government organizations that are calling for the sharing of clinical trial data including the World Health Organization, the US National Institute of Health, US Congress, the European Commission and others. In addition to scientists being allowed to review the studies, doctors could make interpretation for themselves. Patients could as well. New treatments could be developed by fresh sets of eyes looking at the data.
Clinical data sharing has been the topic of discussion for quite some time. What do you think will be the catalyst for Pharma sharing their clinical trial data in the future?